Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
22 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Liquidia Corporation’s names, not what it holds today.
Patents granted
22
22 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 4 in 2023
Applications published
45
1 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'09'10'11'12'13'14'15'16'17'19'20'21'22'23'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
LIQUIDIA TECHNOLOGIES, INC. a subsidiary
US, as the owner printed on each patent
41 publishedLiquidia Technologies, Inc. a subsidiary
named as the applicant on its applications, in US
4 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 19, 2025 | 12,390,475 | Dry powder treprostinil for the treatment of pulmonary hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| Sep 5, 2023 | 11,744,836 | Dry powder treprostinil for the treatment of pulmonary hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| Sep 5, 2023 | 11,744,835 | Dry powder treprostinil for the treatment of pulmonary hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| Aug 1, 2023 | 11,712,442 | Dry powder treprostinil for the treatment of pulmonary hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| May 30, 2023 | 11,660,304 | Dry powder treprostinil for the treatment of pulmonary hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| Jan 26, 2021 | 10,898,494 | Dry powder treprostinil for the treatment of pulmonary hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| Jul 21, 2020 | 10,717,209 | Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom | Other special machines | LIQUIDIA TECHNOLOGIES, INC. |
| Aug 29, 2017 | 9,744,715 | Method for producing patterned materials | Other special machines | LIQUIDIA TECHNOLOGIES, INC. |
| May 30, 2017 | 9,662,809 | Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom | Other special machines | LIQUIDIA TECHNOLOGIES, INC. |
| Jan 17, 2017 | 9,545,737 | System and method for producing particles and patterned films | Other special machines | LIQUIDIA TECHNOLOGIES, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 30, 2025 | 2025/0332175 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| Nov 2, 2023 | 2023/0346799 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. · patent 12,390,475 granted from it |
| Aug 18, 2022 | 2022/0257608 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. · patent 11,660,304 granted from it |
| Nov 18, 2021 | 2021/0353641 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. · patent 11,744,836 granted from it |
| Nov 18, 2021 | 2021/0353640 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. · patent 11,744,835 granted from it |
| Oct 14, 2021 | 2021/0315915 | PHARMACEUTICAL COMPOSITIONS OF RIBAVIRIN | Pharmaceuticals | Liquidia Technologies, Inc. |
| Mar 18, 2021 | 2021/0077504 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. · patent 11,712,442 granted from it |
| Oct 3, 2019 | 2019/0298854 | DRUG DELIVERY PARTICLES | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| Jul 11, 2019 | 2019/0209538 | Precision Controlled Load and Release Particles for Post-Operative Pain | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. |
| May 23, 2019 | 2019/0151332 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | Pharmaceuticals | LIQUIDIA TECHNOLOGIES, INC. · patent 10,898,494 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.